Cuproptosis-Related lncRNAs Modulate the Prognosis of MIBC by Regulating the Expression Pattern of Immunosuppressive Molecules Within the Tumor Microenvironment

References

• Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895–1904. doi:10.1007/s00345-019-02984-4
   PubMed Web of Science ®Google Scholar
• Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 global cancer statistics? Cancer Commun. 2019;39(1):22. doi:10.1186/s40880-019-0368-6
   PubMed Web of Science ®Google Scholar
• Álvarez-Maestro M, Guerrero-Ramos F, Rodríguez-Faba O, Domínguez-Escrig JL, Fernández-Gómez JM. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC). Actas Urol Esp. 2021;45(2):93–102. doi:10.1016/j.acuro.2020.08.003
   PubMed Web of Science ®Google Scholar
• Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104. doi:10.1016/j.eururo.2020.03.055
   PubMed Web of Science ®Google Scholar
• Sanli O, Dobruch J, Knowles MA, et al. Bladder cancer. Nat Rev Dis Primers. 2017;3:17022. doi:10.1038/nrdp.2017.22
   PubMed Web of Science ®Google Scholar
• Duan WJ, He RR. Cuproptosis: copper-induced regulated cell death. Sci China Life Sci. 2022;65(8):1680–1682. doi:10.1007/s11427-022-2106-6
   PubMed Web of Science ®Google Scholar
• Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022;32(5):417–418. doi:10.1038/s41422-022-00653-7
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang L, Zhou F. Cuproptosis: a new form of programmed cell death. Cell Mol Immunol. 2022;19(8):867–868. doi:10.1038/s41423-022-00866-1
   PubMed Web of Science ®Google Scholar
• Ge EJ, Bush AI, Casini A, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022;22(2):102–113. doi:10.1038/s41568-021-00417-2
   PubMed Web of Science ®Google Scholar
• Lv H, Liu X, Zeng X, et al. Comprehensive analysis of cuproptosis-related genes in immune infiltration and prognosis in melanoma. Front Pharmacol. 2022;13:930041. doi:10.3389/fphar.2022.930041
   PubMed Web of Science ®Google Scholar
• Bian Z, Fan R, Xie L. A novel cuproptosis-related prognostic gene signature and validation of differential expression in clear cell renal cell carcinoma. Genes. 2022;13(5):851. doi:10.3390/genes13050851
   PubMed Web of Science ®Google Scholar
• Li SR, Bu LL, Cai L. Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway. Signal Transduct Target Ther. 2022;7(1):158. doi:10.1038/s41392-022-01014-x
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981. doi:10.1158/0008-5472.CAN-16-2634
   PubMed Web of Science ®Google Scholar
• Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36(41):5661–5667. doi:10.1038/onc.2017.184
   PubMed Web of Science ®Google Scholar
• Zhang L, Li B, Peng Y, et al. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: a gene expression-based study. Oral Oncol. 2020;110:104943. doi:10.1016/j.oraloncology.2020.104943
   PubMed Web of Science ®Google Scholar
• Woerl AC, Eckstein M, Geiger J, et al. Deep learning predicts molecular subtype of muscle-invasive bladder cancer from conventional histopathological slides. Eur Urol. 2020;78(2):256–264. doi:10.1016/j.eururo.2020.04.023
   PubMed Web of Science ®Google Scholar
• Cobine PA, Brady DC. Cuproptosis: cellular and molecular mechanisms underlying copper-induced cell death. Mol Cell. 2022;82(10):1786–1787. doi:10.1016/j.molcel.2022.05.001
   PubMed Web of Science ®Google Scholar
• Zhao J, Guo S, Schrodi SJ, He D. Cuproptosis and cuproptosis–related genes in rheumatoid arthritis: implication, prospects, and perspectives. Front Immunol. 2022;13:930278. doi:10.3389/fimmu.2022.930278
   PubMed Web of Science ®Google Scholar
• Bao JH, Lu WC, Duan H, et al. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas. Front Immunol. 2022;13:933973. doi:10.3389/fimmu.2022.933973
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zeng X, Wu Y, Liu Y, Zhang X, Song Z. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in Hepatocellular carcinoma. Front Immunol. 2022;13:925618. doi:10.3389/fimmu.2022.925618
   PubMed Web of Science ®Google Scholar
• Ahmad S, Abbas M, Ullah M, et al. Long non-coding RNAs regulated NF-κB signaling in cancer metastasis: micromanaging by not so small non-coding RNAs. Semi Cancer Biol. 2022;85:155.
   PubMed Web of Science ®Google Scholar
• Su S, Yeh C, Lin C, et al. A novel melatonin-regulated lncRNA suppresses TPA-induced oral cancer cell motility through replenishing PRUNE2 expression. J Pineal Res. 2021;71(3):e12760. doi:10.1111/jpi.12760
   PubMed Web of Science ®Google Scholar
• Sun Z, Jing C, Xiao C, Li T. An autophagy-related long non-coding RNA prognostic signature accurately predicts survival outcomes in bladder urothelial carcinoma patients. Aging. 2020;12(15):15624–15637. doi:10.18632/aging.103718
   PubMedGoogle Scholar
• Rao Y, Liu H, Yan X, Wang J. In silico analysis identifies differently expressed lncRNAs as novel biomarkers for the prognosis of thyroid cancer. Comput Math Methods Med. 2020;2020:3651051. doi:10.1155/2020/3651051
   PubMed Web of Science ®Google Scholar
• Qiu Z, He L, Yu F, Lv H, Zhou Y, Ding X. LncRNA FAM13A-AS1 regulates proliferation and apoptosis of cervical cancer cells by targeting miRNA-205-3p/DDI2 axis. J Oncol. 2022;2022:8411919. doi:10.1155/2022/8411919
   PubMed Web of Science ®Google Scholar
• Wu S, Liu J, Wang X, Li M, Chen Z, Tang Y. Aberrant expression of the long non-coding RNA GHRLOS and its prognostic significance in patients with colorectal cancer. J Cancer. 2017;8(19):4040–4047. doi:10.7150/jca.21304
   PubMed Web of Science ®Google Scholar
• Zhang X, Jiang Y, Xie Y, Leng X, Song F. Comprehensive analysis of lncRNAs associated with the pathogenesis and prognosis of gastric cancer. DNA Cell Biol. 2020;39(2):299–309. doi:10.1089/dna.2019.5161
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang Q, Lou Q, et al. Differential analysis of lncRNA, miRNA and mRNA expression profiles and the prognostic value of lncRNA in esophageal cancer. Pathol Oncol Res. 2020;26(2):1029–1039. doi:10.1007/s12253-019-00655-8
   PubMed Web of Science ®Google Scholar
• Xu S, Liu D, Chang T, et al. Cuproptosis-associated lncRNA establishes new prognostic profile and predicts immunotherapy response in clear cell renal cell carcinoma. Front Genet. 2022;13:938259. doi:10.3389/fgene.2022.938259
   PubMed Web of Science ®Google Scholar
• Han J, Hu Y, Liu S, Jiang J, Wang H, Pan J. A newly established cuproptosis-associated long non-coding RNA signature for predicting prognosis and indicating immune microenvironment features in soft tissue sarcoma. J Oncol. 2022;2022:8489387. doi:10.1155/2022/8489387
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548. doi:10.1038/nature25501
   PubMed Web of Science ®Google Scholar
• Hayashi H, Sugawara S, Fukuda Y, et al. A randomized Phase II study comparing nivolumab with carboplatin-pemetrexed for EGFR-mutated NSCLC with resistance to EGFR tyrosine kinase inhibitors (WJOG8515L). Clin Cancer Res. 2022;28(5):893–902. doi:10.1158/1078-0432.CCR-21-3194
   PubMed Web of Science ®Google Scholar
• Sharma P, Siefker-Radtke A, de Braud F, et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: checkMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results. J Clin Oncol. 2019;37(19):1608–1616. doi:10.1200/JCO.19.00538
   PubMed Web of Science ®Google Scholar
• Necchi A, Raggi D, Gallina A, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020;77(4):439–446. doi:10.1016/j.eururo.2019.10.026
   PubMed Web of Science ®Google Scholar